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Abstract 
Background  Corrected QT dispersion (cQTD) has been correlated with non-uniform ventricular repolarisation and increased mortal-
ity. In patients with aortic stenosis, cQTD has been shown improved after surgical valve replacement, but the effects of transcatheter aortic 
valve implantation (TAVI) are unknown. Therefore, we sought to explore the frequency, predictors and prognostic effects of defective cQTD 
recovery at 6 months after TAVI. Methods  A total of 222 patients underwent TAVI with the Medtronic-CoreValve System between No-
vember 2005 and January 2012. Patients who were on class or  antiarrhythmics or on chronic haemodialysis or who developed atrial Ⅰ Ⅰ
fibrillation, a new bundle branch block or became pacemaker dependent after TAVI were excluded. As a result, pre-, post- and follow-up 
ECG (median: 6 months) analysis was available in 45 eligible patients. Defective cQTD recovery was defined as any progression beyond the 
baseline cQTD at 6 months. Results  In the 45 patients, the mean cQTD was 47 ± 23 ms at baseline, 45 ± 17 ms immediately after TAVI 
and 40 ± 16 ms at 6 months (15% reduction, P = 0.049). Compared to baseline, cQTD at 6 months was improved in 60% of the patients 
whereas defective cQTD recovery was present in 40%. cQTD increase immediately after TAVI was an independent predictor of defective 
cQTD recovery at 6 months (per 10 ms increase; OR: 1.89, 95% CI: 1.15–3.12). By univariable analysis, defective cQTD recovery was asso-
ciated with late mortality (HR: 1.52, 95% CI: 1.05–2.17). Conclusions  Despite a gradual reduction of cQTD after TAVI, 40% of the pa-
tients had defective recovery at 6 months which was associated with late mortality. More detailed ECG analysis after TAVI may help to 
avoid late death. 
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1  Introduction  
The natural course of aortic stenosis (AS) is characterised 
by among others cardiac arrhythmia and sudden death in up 
to 34% of the patients.[1–3] Surgical aortic valve replacement 
(AVR) has shown to reduce the risk of sudden death.[3] 
Whether this also holds for patients who undergo tran-
scatheter aortic valve implantation (TAVI), which are char-
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acterised by more advanced age and co-morbid conditions 
than patients who undergo AVR, remains to be elucidated. 
Consistent with the findings of Thomas, et al.,[4] we recently 
found that sudden death accounts for approximately 10% of 
all-cause 1-year mortality after TAVI.[5] 
Although not per se cardiac in origin, it is conceivable 
that late sudden death may be explained or caused by ab-
normalities in ventricular repolarisation. Corrected QT dis-
persion (cQTD) can be used to assess disturbances in the 
homogeneity of ventricular repolarisation and may, there-
fore, help to identify patients who are at increased risk of 
unexplained late death.[6] An increased cQTD reflects in-
homogeneity of ventricular repolarisation and is associated 
with an increased risk of cardiac death in patients with a 
variety of heart diseases.[6–9]  
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A reduction in cQTD has been reported early after AVR 
most likely due to a reduction in afterload, improved coro-
nary flow and early left ventricular mass regression.[10–12] 
Similar effects may be expected after TAVI, yet, as men-
tioned these patients are older with more comorbidities and 
may also have been exposed to a longer period of increased 
left ventricular afterload. We, therefore, sought to explore 
the changes in cQTD and the frequency, predictors and 
prognostic effects of defective cQTD recovery at six months 
after TAVI.  
2  Methods 
2.1  Patients and procedure 
Between November 2005 and January 2012, a total of 
222 consecutive patients with AS underwent trans-arterial 
TAVI with the Medtronic CoreValve System (MCS). In all 
patients, a pre-, post- and follow-up 12-lead ECG was 
available. Patients with atrial fibrillation and those taking 
class I or III antiarrhytmics or on chronic haemodialysis 
were excluded.[13] For the purpose of an accurate assessment 
of cQTD changes over time, patients with a new conduction 
abnormality [left bundle branch block (LBBB), right bundle 
branch block (RBBB), or paced rhythm] immediately or six 
months after TAVI and those with a pre-existent conduction 
abnormality that progressed to a higher degree AV block 
were excluded as well. The final study population, therefore, 
consisted of 45 patients (Figure 1).  
Details of the patient selection, prosthesis and subsequent 
phases of the transfemoral TAVI procedure have been pre-
viously published.[14–16] Briefly, all patients referred for 
TAVI were first seen on the out-patient clinic and then dis-
cussed in the heart team. Treatment decision was based 
upon consensus between an interventional cardiologist and a 
cardiac surgeon and since September 2010 by a team con-
sisting of an interventional cardiologist, cardiac surgeon and 
a clinical cardiologist and/or an echocardiographist. Treat-
ment decision was based upon a weighted assessment of 
risk and benefit of the various treatment modalities on the 
basis of all clinical and technical information of the patient. 
The procedure was performed with the patient under general 
anaesthesia with a temporary pacemaker wire positioned in 
the right ventricle and with default femoral arterial access 
through an 18F sheath. The aortic valve was first crossed 
under fluoroscopic control using a straight wire. This wire 
was exchanged for a stiff support wire followed by balloon 
valvuloplasty (22 or 23 mm × 4 cm) under rapid right ven-
tricular pacing. The valve (available in 26, 29 and 31 mm) 
was then advanced over the aortic arch into the aortic annu-
lus with a target deployment of 4–6 mm below the annulus.  
 
Figure 1.  Flow diagram of ECGs available for serial analysis 
of pre-, post- and 6 month ECGs. 
Patients were extubated before leaving the catheterization 
laboratory or within 2 h after arrival in the cardiac care unit.  
2.2  Electrocardiographic recordings and measurements 
All pre-, post- and follow-up [median: 181, interquartile 
range (IQR): 110-279 days] 12-lead ECGs were recorded at 
a paper speed of 25 mm/s and reprinted at a speed of 50 
mm/s to improve sensitivity and accuracy of the manual 
measurements.[17,18] Inter-observer variability of cQTD mea-
surements were evaluated by comparing the results of 
cQTD analysis between two observers who independently 
from one another analysed the ECGs. Inter-observer vari-
ability, expressed as the mean absolute difference between 
observers, was 8 ± 16 ms as determined in a consecutive 
series of 10 patients (30 ECGs). Intra-observer variability 
was 5 ± 8 ms. 
The following time intervals were measured: PR, QRS, 
RR, QT and JT. The QT interval was considered to reflect 
the ventricular depolarization and repolarisation whereas the 
JT interval only reflects ventricular repolarisation because it 
does not encompass the depolarization phase. 
The QT interval was calculated by measuring the be-
ginning of the QRS complex until the visual return of the T 
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wave to the TP baseline. When a T wave was complicated 
by a U wave, the end of the T wave was defined as the nadir 
between the T and the U waves.[13] Intervals preceded by 
premature beats were not measured. For each lead, wher-
ever possible, three consecutive cycles were measured and 
corrected for the heart rate using the Bazett’s formula.[19,20] 
The average of the three consecutive cycles was used. The 
cJT interval for each interval was calculated by subtracting 
the QRS interval from the cQT interval.[21]  
cQTD was calculated by measuring the cQT interval of 
all 12 ECG leads and defined by the substraction of the 
shortest from the longest interval (maximum minus mini-
mum cQT interval).[6] In case of uncertainty of the defini-
tion of the end of a T wave, the lead disclosing this uncer-
tainty was excluded from analysis. At least nine measurable 
leads were required for the purpose of this study. No at-
tempt was made to correct for missing leads.[22] Defective 
cQTD recovery was defined as any progression beyond the 
baseline cQTD as assessed using follow-up ECGs. The cQTD 
variation (ΔcQTD) was calculated as the difference between 
cQTD before vs. after and before vs. 6 months after TAVI.[23]  
Left and right bundle branch block was defined accord-
ing to the Wold Health Organization and International Soci-
ety and Federation for Cardiology Task Force.[24]  
2.3  Follow-up 
Follow-up information was collected during structured 
out-patient clinic visits after discharge. Survival and cause 
of death was obtained every 6 months by contacting the 
Dutch Civil Register and/or referring cardiologists and/or 
the general practitioners. Sudden and unexpected death was 
defined as a natural, unexpected death due to cardiac causes, 
heralded by an abrupt loss of consciousness within 1 h of 
the onset of acute symptoms in patients who were previ-
ously stable.[8] 
2.4  Statistical analysis 
Categorical variables are presented as frequencies and 
percentages and were compared with the Chi square test or 
Fisher’s exact test. The normality of distributions was as-
sessed with the Shapiro-Wilk test. Normal and skewed con-
tinuous variables are presented as means ± SD and medians 
[interquartile range (IQR)], respectively. The Wilcoxon 
signed-rank test (for continuous variables) and the McNe-
mar test conducted by exact methods (for categorical vari-
ables) were used to perform paired comparisons for pre- 
treatment vs. post-treatment and pre-treatment vs. follow-up 
ECG findings. Multivariable logistic regression including 
all variables with P < 0.05 in the univariable analysis was 
performed to determine the predictive factors of defective 
cQTD recovery. Given the small number of deaths during 
follow-up (n = 7), a univariable Cox regression analysis was 
performed to explore the potential association between de-
fective cQTD recovery and late mortality. A two-sided P < 
0.05 was considered to indicate significance and all statistical 
analyses were performed with SPSS software (version 17). 
In accordance with the institutions policies, every patient 
gave written informed consent for TAVI and the use of 
anonymous clinical, procedural and follow-up data for re-
search in accordance with Institutional Review Board appro-
val. This study complies with the Declaration of Helsinki. 
3  Results 
The baseline characteristics and the serial ECG changes 
are summarized in Table 1 and 2, respectively. Overall, the  
Table 1.  Baseline characteristics of patients undergoing TA-
VI (n = 45). 
Age, yr 78 ± 10 
Men 26 (58) 
Body mass index, kg/m2 25.8 ± 3.8 
New York Heart Association class ≥ III 37 (82) 
Previous cerebrovascular event 12 (27) 
Previous myocardial infarction 7 (16) 
Previous coronary artery bypass graft surgery 13 (29) 
Previous percutaneous coronary intervention 10 (22) 
History of heart failure 18 (40) 
Syncope 5 (11) 
Diabetes mellitus 9 (20) 
Hypertension 27 (60) 
Peripheral vascular disease 5 (11) 
Chronic obstructive pulmonary disease 16 (36) 
Logistic EuroSCORE 12 (9–22) 
Laboratory  
Serum sodium, mmol/L 141 ± 3 
Serum potassium, mmol/L 4.4 ± 0.6 
Serum creatinine, mmol/L 88 (77–112)
Medication  
Beta-blockers 22 (49) 
Digoxin 1 (2) 
Diuretics 23 (51) 
Angiotensin converting enzyme inhibitors 13 (29) 
Echocardiography  
Left ventricular ejection fraction, % 50 ± 13 
Aortic valve area, cm2 0.69 ± 0.2 
Peak gradient, mmHg 75 27 
Mitral regurgitation grade III or greater 3 (7) 
Aortic regurgitation grade III or greater 7 (16) 
Data are expressed as means ± SD, medians (IQR) or numbers (%). TAVI: 
transcatheter aortic valve implantation; IQR: interquartile range. 
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Table 2.  Serial analyses of pre- post- and at follow-up ECGs 
after TAVI. 
 P-value P-value
 
Pre- 
treatment 
Post- 
treatment 
follow- 
up pre- vs. 
post
pre vs. 
follow-up
Entire cohort, n = 45     
Heart rate, beats/min 70 ± 12 75 ± 13 72 ± 12 0.004 0.29 
PR interval, ms 182 ± 28 188 ± 32 180 ± 23 0.33 0.74 
QRS width, ms 124 ± 31 127 ± 31 124 ± 33 0.045 0.69 
cJT interval, ms      
Minimum 285 ± 31 285 ± 24 287 ± 26 0.89 0.92 
Maximum 332 ± 25 330 ± 25 327 ± 26 0.58 0.12 
cQT interval, ms      
Minimum 417 ± 40 427 ± 36 422 ± 40 0.049 0.24 
Maximum 464 ± 33 471 ± 35 462 ± 41 0.091 0.68 
Dispersion 47 ± 23 45 ± 17 40 ± 16 0.82 0.049 
Patients without conduction abnormalities, n = 27  
Heart rate beats/min 70 ± 14 74 ± 15 72 ± 13 0.051 0.48 
PR interval, ms 183 ± 30 186 ± 34 177 ± 26 0.88 0.21 
QRS width, ms 100 ± 8 105 ± 16 100 ± 10 0.045 0.92 
cJT interval, ms      
Minimum 287 ± 33 287 ± 27 290 ± 27 0.64 0.86 
Maximum 338 ± 23 334 ± 28 328 ± 25 0.27 0.052 
cQT interval, ms      
Minimum 396 ± 30 405 ± 20 400 ± 27 0.22 0.47 
Maximum 447 ± 24 452 ± 23 438 ± 26 0.21 0.16 
Dispersion 50 ± 27 47 ± 16 38 ± 16 0.95 0.006 
Data are expressed as means ± SD, medians (IQR) or n (%). TAVI: tran-
scatheter aortic valve implantation; IQR: interquartile range. 
 
average heart rate, QRS duration and minimum cQT inter-
val increased immediately after TAVI, yet all changes re-
turned to baseline values at 6 months. The cQTD decreased 
immediately after TAVI, with a further decline at 6 months 
(47 vs. 45 vs. 40 ms, P = 0.049). In a subgroup of 27 pa-
tients without conduction abnormality before, after and 6 
months after TAVI, the cQTD decreased from 50 ms at 
baseline to 38 ms at 6 months (reduction of 24%, P = 
0.006). 
3.1  Frequency and predictors of defective cQTD 
recovery 
In 27 out of the 45 patients (60%), a reduction in cQTD 
between baseline and follow-up was observed, whereas in 
18 patients (40%) an increase was observed (defective 
cQTD recovery). The individual changes in cQTD are pre-
sented in Figure 2. Details of the baseline characteristics and 
perioperative results grouped according to the occurrence of 
defective cQTD recovery are shown in Table 3 and 4, re-
spectively.  
Patients with defective cQTD recovery had a worse ejec-
tion fraction (45% vs. 54%, P = 0.026), longer minimum 
cQT interval before TAVI (432 ms vs. 407 ms, P = 0.001) 
and an increase in cQTD immediately after TAVI (ΔcQTD: 
+13 ms vs. −13 ms, P = 0.002) in comparison to patients 
without defective cQTD recovery. The independent predic-
tors of defective cQTD recovery are listed in Table 5.  
3.2  Prognostic effects of defective cQTD recovery 
The median follow-up was 14 months (IQR: 7–23); sev-
en patients (16%) died at a median of 11 months (IQR: 6–15) 
after TAVI. Four deaths occurred in patients with defective 
cQTD recovery (cardiac death: 50%) and three deaths in 
patients without defective cQTD recovery (cardiac death: 
0%). By univariable analysis, a higher baseline serum crea-
tinine (per 10 mmol/L increase, HR: 1.09; 95% CI: 
1.03–1.16) and defective cQTD recovery (ΔcQTD at 6 
months, per 10 ms decrease, HR: 1.52; 95% CI: 1.05–2.17) 
were significantly associated with late mortality. 
 
Figure 2.  Individual changes in cQTD during follow-up according to the occurrence of defective cQTD recovery. cQTD: corrected 
QT dispersion.
486 Nuis RJ, et al. Defective QTD recovery after TAVI 
 
Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com 
Table 3.  Baseline characteristics grouped according to the 
occurrence of defective cQTD recovery at 6 months after TAVI. 
Defective cQTD recovery 
Variable 
No = 27 Yes = 18 P
Age, yrs 78 ± 10 79 ± 11 0.78
Men 13 (48) 13 (72) 0.11
Body mass index, kg/m2 25.8 ± 3.7 25.8 ± 4.1 0.96
New York Heart Association class ≥ III 21 (78) 16 (89) 0.45
Previous cerebrovascular event 9 (33) 3 (17) 0.31
Previous myocardial infarction 2 (7) 5 (28) 0.098
Previous coronary artery bypass  
graft surgery 
6 (22) 7 (39) 0.23
Previous percutaneous coronary  
intervention 
7 (26) 3 (17) 0.72
History of heart failure 8 (30) 10 (56) 0.082
Syncope 4 (15) 1 (6) 0.63
Diabetes mellitus 4 (15) 5 (28) 0.45
Hypertension 15 (56) 12 (67) 0.46
Peripheral vascular disease 3 (11) 2 (11) 1.0 
Chronic obstructive pulmonary disease 11 (41) 5 (28) 0.37
Logistic EuroSCORE 12 (8–21) 15 (10–25) 0.31
Laboratory    
Serum sodium, mmol/L 141 ± 4 141 ± 3 0.87
Serum potassium, mmol/L 4.5 ± 0.5 4.3 ± 0.6 0.33
Serum creatinine, mmol/L 82 (73–112) 91 (86–126) 0.084
Medication    
Beta-blockers 12 (44) 10 (56) 0.47
Digoxin 0 1 (6) 0.40
Diuretics 11 (41) 12 (67) 0.13
Angiotensin converting enzyme inhibitors 8 (30) 5 (28) 0.89
Echocardiography    
Left ventricular ejection fraction, %  54 ± 12  45 ± 13 0.026
Aortic valve area, cm2 0.69 ± 0.2 0.68 ± 0.3 0.79
Peak gradient, mmHg 79 30 68 19 0.18
Mitral regurgitation grade III or greater 2 (8) 1 (6) 1.0 
Aortic regurgitation grade III or greater 5 (19) 2 (11) 0.50
Data are expressed as means ± SD, medians (IQR) or n (%). cQTD: cor-
rected QT dispersion; IQR: interquartile range; TAVI: transcatheter aortic 
valve implantation.  
4  Discussion 
In this study of 45 patients with aortic stenosis, we found 
that the average cQTD-time was significantly reduced at 6 
months after TAVI. Yet, defective cQTD recovery was 
present in 40% of the patients. Worsening of cQTD imme-
diately after TAVI was an independent predictor of defec-
tive cQTD recovery at 6 months, which in turn showed a 
directional signal of a higher risk of late mortality.  
cQTD can be used to determine non-uniform ventricular 
repolarization and is increased in a variety of cardiac condi-
tions such as long QT syndrome, chronic heart failure, hy-
pertrophic cardiomyopathy, myocardial infarction and in 
patients with left ventricular hypertrophy associated with 
aortic stenosis.[6–9] In these patients, increased cQTD has 
been associated with susceptibility to ventricular arrhyth-
mias, cardiac mortality and unexplained sudden death.[17] 
Yet, in patients with aortic stenosis, cQTD has been shown 
to reduce early after surgical aortic valve replacement, 
which is attributed to a reduced afterload, improved coro-
nary flow and early left ventricular mass regression.[10–12]  
Table 4.  ECG and peri-operative results grouped according 
to the occurrence of defective cQTD recovery at 6 months after 
TAVI. 
Defective cQTD recovery 
Variable 
No = 27 Yes = 18 P-value
Heart rate, beats/min    
Pre-treatment 70 ± 13 70 ± 10 0.90
Post-treatment 73 ± 14 77 ± 12 0.37
Follow-up 70 ± 11 74 ± 13 0.26
PR interval, ms    
Pre-treatment 183 ± 30 181 ± 25 0.85
Post-treatment 184 ± 33 193 ± 30 0.41
Follow-up 179 ± 21 181 ± 28 0.83
Minimum cJT interval, ms    
Pre-treatment 280 ± 34 292 ± 26 0.21
Post-treatment 290 ± 25 279 ± 22 0.12
Follow-up 292 ± 24 281 ± 28 0.17
Maximum cJT interval, ms    
Pre-treatment 336 ± 25 325 ± 25 0.17
Post-treatment 334 ± 28 324 ± 19 0.24
Follow-up 327 ± 23 327 ± 30 0.94
Minimum cQT interval, ms    
Pre-treatment 407 ± 39 432 ± 37 0.036
Post-treatment 427 ± 35 427 ± 38 0.99
Follow-up 420 ± 38 425 ± 44 0.69
Maximum cQT interval, ms    
Pre-treatment 463 ± 32 465 ± 36 0.81
Post-treatment 470 ± 36 473 ± 34 0.82
Follow-up 456 ± 35 471 ± 48 0.23
cQTD variation 
(pre vs. post-treatment), ms 
−13 ± 31 +13 ± 31 0.002
cQTD variation (pre vs. follow-up), ms −20 ± 24 +13 ± 13 < 0.001
Myocardial injury ≤ 48 h    
Maximum troponin T 0.22 ± 0.21 0.21 ± 0.20 0.93
Maximum CKMB 13 ± 16 8 ± 6 0.39
Echocardiography < 7 days    
Peak gradient 19 ± 9 18 ± 8 0.71
Mitral regurgitation grade III or greater 1 (4%) 2 (12%) 0.55
Aortic regurgitation grade III or greater 3 (12%) 1 (6%) 0.53
Data are expressed as means ± SD or n (%). CKMB: creatine kinase MB; 
cQTD: corrected QT dispersion; TAVI: transcatheter aortic valve implantation. 
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Table 5.  Independent predictors of defective cQTD recovery 
after TAVI. 
Crude OR Adjusted OR
Variable 
(95% CI) (95% CI) 
P 
Left ventricular ejection fraction 
(per 10% decrease) 
1.78  
(1.04–3.03) 
1.61  
(0.84–3.09)
0.15 
Pre-operative minimum cQT  
interval (per 10 ms increase) 
1.20  
(1.00–1.42) 
1.12  
(0.91–1.39)
0.28 
cQTD variation (pre vs. post)  
(per 10 ms decrease) 
1.98  
(1.25–3.14) 
1.89  
(1.15–3.12)
0.012 
cQTD: corrected QT dispersion; TAVI: transcatheter aortic valve implantation. 
 
This has also been demonstrated in patients with severe con-
genital AS undergoing percutaneous balloon valvuloplasty.[25] 
The findings of the present study indicate that cQTD re-
covery after TAVI does not occur immediately after the 
procedure but is a time related phenomenon that is not com-
plete at 6 months (40% of the patients still had a defective 
cQTD recovery). This is in contrast with the findings of 
Sarubbi, et al.[25] who showed a 23% cQTD reduction imme-
diately after balloon valvuloplasty and those of Tsai, et al.[11] 
who demonstrated a 48% reduction by 6 days after AVR. 
The evident and immediate cQTD reduction following 
AVR contrasts with our findings of a delayed and incom-
plete cQTD reduction after TAVI. This can be explained by 
patient-related factors since TAVI patients are in general 
older than patients who undergo surgical valve replacement 
and, therefore, have more pronounced age-related degenera-
tive changes of the myocardium. In addition, TAVI patients 
may suffer from longer periods of elevated afterload in 
comparison to surgical patients due to a longer time interval 
to clinical detection and treatment delay.[26,27] They may 
therefore, have more extensive cQTD and less response to 
early changes following afterload correction.  
The observed increase in cQTD immediately after TAVI 
in patients with a defective cQTD recovery during follow- 
up could be due to an early impairment of the conductive 
system not appearing at the 12-lead ECG evaluation. In 
these particular patients, the reduction in afterload, im-
proved coronary flow and left ventricular mass regression 
may not be sufficient to improve the cQTD at follow-up. 
This phenomenon could be particularly common after 
CoreValve implantation considering the frequent occurrence 
of new conduction defects associated with this device.[16] 
The latter may also explain why a significant number of 
patients had discordant cQTD changes (i.e., an initial de-
crease in cQTD from baseline to post-TAVI, followed by an 
increase at follow-up), which occurred in 46% of patients. 
The prognostic value of cQTD is subject of debate.[17] 
Yet, some studies demonstrated that cQTD is strongly asso-
ciated with malignant arrhythmias and cardiac mortality.[6,18] 
As mentioned, cQTD recovery was incomplete at six months 
in the present population. Although we lack the power to 
demonstrate an association with malignant arrhythmia and 
sudden cardiac death, it is conceivable that these patients are 
at increased risk of late sudden death. Of note, the causes of 
death in patients with defective cQTD recovery were sud-
den death (n = 1), myocardial infarction (n = 1) and terminal 
kidney failure (n = 2), whereas patients without defective 
cQTD recovery died because of a pneumonia (n = 1), sepsis 
(n = 1) and a perforated diverticulitis (n = 1). The clinical 
relevance of defective cQTD recovery was previously 
demonstrated by Chalil, et al.[28] who demonstrated that in-
creased cQTD duration independently predicts sudden 
death/resuscitation in patients undergoing cardiac resyn-
chronization therapy. 
4.1  Limitations 
cQTD is known to be an approximate of repolarisation 
abnormalities. Yet, given the absence of an underlying 
pathophysiologic explanation, the observation of (defective) 
cQTD recovery is of observational nature. We also acknow-
ledge the fact that drugs other than class I or III antiarrhyt-
mic drugs (i.e., antidepressants) may have affected the cQT 
recovery assessment and the fact that only quarter of the 
patients who underwent TAVI were eligible mainly because 
of the frequent occurrence of new conduction abnormalities 
associated with TAVI. Another limitation of the present 
study is that it cannot indicate which measures have to be 
taken in case of defective cQTD recovery. The question is 
whether one should first stop all drugs that may have such 
an effect or whether one even should consider the implanta-
tion of an automated implantable cardioverter-defibrillator. 
Data in larger series of patients stemming from multicenter 
observations are needed to confirm or to rule out the current 
observations, the precise timing and/or delay of recovery and 
to elucidate the role of potential measures to be taken. At last, 
the inter- and intra-observer variability of approximately 20% 
should be taken into account when interpreting the study 
results, and warrants future research to confirm our findings. 
4.2  Conclusions 
TAVI was associated with a gradual reduction of cQTD 
during the follow-up period. Defective cQTD recovery was 
seen in 40% of the patients. This was predominantly seen in 
patients with an increase in cQTD immediately after TAVI 
and was associated with a higher risk of late mortality. In 
addition to the regular follow-up examinations after TAVI, 
it is conceivable that more detailed analysis of the ECG may 
help to identify patients at risk of late unexpected death.  
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